A risky but often lifesaving surgery that removes damaged parts of the small intestine can leave patients facing a new threat: serious liver damage with no available treatment. Now, scientists have ...

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted ...

Paul, a liver cancer survivor, and his wife Emma share their journey of recovery, caregiving and finding balance in life ...

Confirmed objective responses were observed at 8.6 and 10 mg/kg q3w, with a high overall disease control rate in late-line metastatic colorectal cancer. Progression-free survival estimates near 7 ...

A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to ...

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The ...

In Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps, our experts delve into the following critical questions: We have now covered se ...

A new study suggests that suppressing a cellular enzyme long considered protective against fatty liver disease could have unexpected long-term consequences.

Antibiotic use among patients with GI and liver cancers treated with ICI is linked to significantly worse OS, progression-free survival, and disease control rates.

Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - ...

After being diagnosed with stage 4 colorectal cancer in 2024, Amy Piccioli underwent a liver transplant from a close family friend that helped her achieve “no evidence of disease.” ...